Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06947993 | Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | PHASE2 | RECRUITING | 224 | — | — | May 16, 2025 | Dec 22, 2028 | Dec 22, 2025 | 99 | United States, Argentina +15 |
EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.
| Arm | Type | Description |
|---|---|---|
| GHZ339 Dose A | EXPERIMENTAL | Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 |
| GHZ339 Dose B | EXPERIMENTAL | Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2 |
| GHZ339 Dose C | EXPERIMENTAL | Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2 |
| GHZ339 Dose D | EXPERIMENTAL | Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2 |
| Placebo | PLACEBO_COMPARATOR | Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 |
| Name | Type | Description |
|---|---|---|
| GHZ339 | DRUG | GHZ339 administered at dose A, B, C and D |
| Placebo | DRUG | Matching placebo |
Key Inclusion Criteria of the master protocol: * Able and willing to sign the informed consent (IC) * Patients with a diagnosis of AD and onset of disease for at least 1 year * Moderate to severe AD Key Exclusion Criteria of the master protocol: * Participants with a clinically significant medica...